NL-OMON44446已完成不适用
Excretion balance, pharmacokinetics and metabolism of S44819 after single administration of [14C]-S44819 in young healthy male volunteers. A phase 1 monocentre open-label study. - S 44819 - PK - Mass balance study
Institut de Recherches Internationales Servier (I.R.I.S.)0 个研究点目标入组 4 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 4
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 64（—）
入选标准
- •- healthy male caucasian participants aged between 18-45 years inclusively
- •- 18.5 kg/m²*BMI* 30.0 kg/m²
- •- Body weight * 50 kg
- •- Be a non-smoker (or having not smoked for at least 6 months prior to the selection visit)
排除标准
- •Suffering from hepatitis B, hepatitis C, cancer or HIV/AIDS. In case of participation in another drug study within 90 days before the start of this study. Donation of blood derivates or loss of more than 50 mL of blood within the 90 days before the day of selection, during the study and 3 months following completion of the study.
研究者
相似试验
已完成
不适用
Excretion balance, pharmacokinetics and metabolism of S 47445 after single oral administration of 20mg [14C]-S 47445 in young healthy male volunteers.dementiaNL-OMON35510Institut de Recherches Internationales Servier I.R.I.S4
已完成
不适用
Excretion balance, pharmacokinetics and metabolism of S 38844 after single oral dose administration of [14C]-S 38844 in healthy male volunteers.cardiovascular diseasesheart- and (blood) vessel diseases1008220610057166NL-OMON36850Institut de Recherches Internationales Servier I.R.I.S6
终止
1 期
A Study in Healthy Men to Test How BI 1265162 is Taken up and Processed by the BodyHealthy VolunteersNCT04267276Boehringer Ingelheim7
已完成
不适用
Absorption, metabolism, excretion, and the determination of absolute bioavailability of Niraparib in subjects with cancercancerand that may benefit from treatment with a PARP inhibitormetastatic or locally advanced solid tumors that have failed to respond to standard therapyhave progressed despite standard therapyor for which no standard therapy existsrefuse standard therapy10027655NL-OMON41940TESARO, Inc12
已完成
1 期
Mass Balance, Pharmacokinetics and Metabolism Study of AlisertibAdvanced Solid TumorsLymphomaNCT01714947Millennium Pharmaceuticals, Inc.3